HAEMONETICS CORP — Director's Dealing 2024

Sep 3, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HAEMONETICS CORP (HAE)
CIK: 0000313143
Period of Report: 2024-08-29

Reporting Person: Simon, Christopher (Director, President & CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-08-29	Common Stock	J	39704	$75.56	Disposed	322838	Direct

Footnotes

F1: On August 29, 2024, in an asset substitution transaction, Mr. Simon transferred 39,704 shares of the Issuer's common stock to the Simon Family Irrevocable Trust for the benefit of the reporting person's children, in exchange for cash in the amount of $3,000,034, with the number of shares determined by averaging the high and low sales prices of the Issuer's common stock as reported by the New York Stock Exchange on August 29, 2024. The substitution was made in accordance with the terms of the trust, which has an independent trustee.

F2: This number includes unvested restricted stock units previously reported.